| Identification | Back Directory | [Name]
MGAT2-IN-1 | [CAS]
1800025-30-2 | [Synonyms]
MGAT2-IN-1
MGAT2 inhibitor 1
MGAT2 IN 1,MGAT-2-IN-1,MGAT2IN1
1H-Indole-5-sulfonamide, N-(4-chloro-2,6-difluorophenyl)-2,3-dihydro-1-[5-[1-methyl-3-(trifluoromethyl)-1H-pyrazol-5-yl]-2-pyrimidinyl]-7-(2-oxo-1-pyrrolidinyl)- | [Molecular Formula]
C27H21ClF5N7O3S | [MDL Number]
MFCD31544334 | [MOL File]
1800025-30-2.mol | [Molecular Weight]
654.01 |
| Chemical Properties | Back Directory | [Boiling point ]
838.7±75.0 °C(Predicted) | [density ]
1.66±0.1 g/cm3(Predicted) | [storage temp. ]
Store at -20°C | [solubility ]
DMSO : ≥ 125 mg/mL (191.13 mM) | [form ]
Solid | [pka]
8.30±0.20(Predicted) | [color ]
White to gray |
| Hazard Information | Back Directory | [Uses]
TP-020 (MGAT2-IN-1) is an orally active inhibitor of monoacylglycerol acyltransferase (MGAT2) with IC50 of 7.8 and 2.4 nM for human and mouse MGAT2, respectively. | [in vivo]
TP-020 (3, 10 mg/kg, p.o.) dose-dependently suppresses plasma TG elevation, and plasma CM/TG AUC in mice. TP-020 does not decrease MG absorption but inhibits MGAT2-dependent TG/DG resynthesis. In the lipid utilization analysis, TP-020 significantly increases free fatty acid (FFA) and acylcarnitine levels. TP-020 (30 mg/kg) also significantly reduces food intake dose dependently, suppresses BW gains. TP-020 shows anti-diabetic effects in mice[1]. | [storage]
Store at -20°C | [References]
[1] Take K, et al. Pharmacological Inhibition of Monoacylglycerol O-Acyltransferase 2 Improves Hyperlipidemia, Obesity, and Diabetes by Change in Intestinal Fat Utilization. PLoS One. 2016 Mar 3;11(3):e0150976. DOI:10.1371/journal.pone.0150976 |
|
| Company Name: |
BOC Sciences
|
| Tel: |
|
| Website: |
https://www.bocsci.com |
|